MolMed: Germany confirms the reimbursement of Zalmoxis® at a price of 130,000 Euro per infusion.
Milan (Italy), February 4th, 2019 – MolMed S.p.A. (MLMD.MI), clinical stage biotechnology company focusing on research, development, manufacturing and clinical validation of cell & gene therapies for the treatment of cancer and rare diseases, is pleased to announce that the German public health insurance system (GKV) has approved the reimbursement of Zalmoxis® at a price of 130,000 Euros per infusion (ex-factory price excluding VAT). The cost per patient will be based on the approved dosing schedule, which allows from 1 to 4 infusions, until the immune-reconstitution is reached, and on the clinical experience, that shows an average of just over 2 infusions per patient.
The agreement will be in force as of February 15th, 2019 and follows the authorization granted in February 2018 and the consequent drug evaluation and price negotiation process regulated by the AMNOG system, according to which the G-BA Federal Committee recognized to MolMed’s therapy a benefit for the treatment of adult patients with high risk relapse leukemia in haplo-identical haematopoietic stem cell transplantation (haplo-HSCT).
Thanks to this agreement, valid for the next 24 months, Zalmoxis® could be prescribed not only in the 2 transplant centres authorized hitherto, but in all the bone marrow transplant centres operating in Germany.
Riccardo Palmisano, MolMed’s CEO commented: “We are very glad for this result, obtained after a rigorous evaluation process and an in-depth discussion with representatives of the German public health insurance system, which once again confirms the therapeutic value of Zalmoxis. This new recognition reinforces our search for a new commercial partner, after the return of the commercial rights for all European countries to MolMed last year in mid-November”.